Frequently Asked Questions
Evidence-based answers to the most common questions about cellular therapy, safety, eligibility, costs, and expected outcomes.
About BioCells Medical
BioCells Medical is a regenerative medicine clinic based in Warsaw, Poland, specialising in personalised cellular therapy for neurological, autoimmune, and neurodegenerative conditions. Every protocol is developed individually based on clinical data, the patient's functional status, and medical board review. The full cellular therapy cycle — from cell collection and cultivation through testing and quality control — is performed in an in-house certified laboratory. Since 2013, more than 2,500 patients from over 20 countries have completed treatment, with continued support both during therapy and after its completion. The focus is on measurable clinical outcome and long-term stabilisation of the patient's condition.
Three key differences. We control the entire process: all therapeutic components are produced in-house — no outsourcing, no commercial tissue banks, no off-the-shelf products. Each protocol is developed individually based on molecular profiling, immunological assessment, and medical board review — no template schemes. We measure outcomes on validated clinical scales (ALSFRS-R, EDSS, UPDRS, GMFCS, and others) and maintain our own patient registry since 2013. We rely on data and transparent outcome reporting, not on marketing promises.
Our clinic and certified cell laboratory are in Warsaw, Poland. We also have a research presence in Boston, USA.
Safety & Science
BioCells Medical's therapeutic protocols are developed and executed in accordance with European medical standards at our certified laboratory in Warsaw, Poland. Clinically validated cell processing methods are used, with full quality-control documentation for every batch. Mesenchymal stem cells (MSCs) hold immunoprivileged status: they are characterised by low HLA-I expression, absent HLA-II, and consequently a minimal risk of immune response in both autologous and allogeneic applications. Allogeneic protocols do not require immunosuppression. The clinical registry has been maintained since 2013 and contains data from more than 2,500 patients with neurological, neurodegenerative, autoimmune, and neuromuscular conditions. Based on these data, the safety profile is assessed as high. Monitoring continues during treatment and after its completion: scheduled follow-up consultations, biomarker assessments, and wearable devices for real-time monitoring are used.
Programmes are based on a multi-component approach configured individually for each patient. Mesenchymal stem cells (MSCs) — multipotent cells with immunomodulatory, anti-inflammatory, and regenerative properties. T-regulatory cells (T-regs) — specialised immune cells aimed at restoring immune balance without systemic immunosuppression. Exosomes — purified cell-derived vesicles that carry signalling molecules and participate in intercellular communication. Personalised neurostimulation — non-invasive, precisely calibrated stimulation targeting dysfunctional neural networks. Peptide protocols — individually selected bioactive peptides addressing metabolic and inflammatory processes. The combination of components, their dosage, and sequencing are determined by the medical board based on diagnosis, disease stage, biomarker profile, and the patient's functional status.
Mesenchymal stem cells (MSCs) carry immunoprivileged properties: they are characterised by low HLA class I expression and absent HLA class II, which determines their low immunogenicity. In autologous protocols, the patient's own cells are used, harvested from bone marrow (a small volume, typically 3–5 ml, under local anaesthesia), ensuring full biological compatibility. Allogeneic protocols (certified donor cells) are applied in clinically justified cases and rely on the immunoprivileged status of MSCs, which allows their use without immunosuppression. Before administration, every cell batch undergoes mandatory testing for viability, sterility, and functional activity.
The most commonly reported reactions are mild and self-limiting: slight fatigue, low-grade fever (37.2–37.8°C), or localised discomfort at the bone marrow harvesting site. Such reactions resolve spontaneously within 12–24 hours and do not require medical intervention. Throughout treatment and after its completion, systematic medical monitoring is provided: biomarker assessments, scheduled consultations, and remote monitoring via wearable devices. A personal medical coordinator is assigned to each patient, ensuring direct medical communication and continuity of care.
Eligibility & Evaluation
Cellular therapy is applied in neurological, neurodegenerative, autoimmune, and neuromuscular conditions, including cases with insufficient response to standard treatment. The clinic works with a wide range of progressive conditions, including ALS, multiple sclerosis, Parkinson's disease, dementia, autism spectrum disorder, cerebral palsy, peripheral neuropathies, muscular dystrophies, and other conditions. Indications are determined individually, taking into account the diagnosis, disease stage, rate of progression, current therapy, and overall functional status. The first step is a consultation and a preliminary review of the medical documentation, followed by assessment by the medical board. The decision regarding further treatment is made after receiving the individualised plan.
The primary contraindications include active malignancies (cancer requiring ongoing treatment), uncontrolled systemic infections, severe organ failure unrelated to the target condition, and certain haematological conditions affecting cell processing. Each case is evaluated individually by the medical board. In some situations, re-evaluation is possible after stabilisation of a concurrent condition or adjustment of current therapy. Contraindications are addressed already at the initial consultation: if cellular therapy is not feasible, this is discussed directly.
In most cases — yes. Cellular protocols are integrated into existing therapy and used alongside it, not instead of it. Standard medications, including levodopa, disease-modifying therapies, immunosuppressants, and other prescribed treatments, are generally continued. The current therapy is reviewed during the medical consultation. Where necessary, targeted adjustments may be recommended before or during treatment. All changes are agreed in advance.
Such situations are rare. The multi-stage pre-evaluation — review of medical documentation, laboratory tests, and a video consultation with the medical team — identifies most limitations before travel. During the on-site examination, additional clinical findings may emerge (for example, a previously undiagnosed infection or significant changes in laboratory values). In such cases, the decision is reconsidered in light of the patient's current condition. Treatment may be temporarily postponed until the condition is stabilised, or the protocol may be adjusted. Medical justification and treatment safety remain the priority.
Results & Follow-Up
Initial therapeutic response is typically observed within 2–6 weeks and depends on the diagnosis and individual patient characteristics. A sustained effect develops gradually — over 3–6 months as regenerative, immunomodulatory, and neuroprotective mechanisms take effect. According to clinical registry data, stabilisation rates range from 68% to 82% depending on the diagnosis. Assessment is carried out using validated clinical scales (ALSFRS-R, EDSS, UPDRS, GMFCS/GMFM, CARS/ABC, and others). Stabilisation is defined as the absence of measurable functional decline over an observation period of at least 6 months. Some patients show additional functional improvement. Results depend on the diagnosis, disease stage, age, comorbidities, and adherence to recommendations. Expectations are framed on the basis of clinical data already at the initial consultation.
Post-treatment follow-up is organised as a structured, objective, and continuous process. A comprehensive approach is used. Medical monitoring — wearable devices track key health metrics in real time and transmit data to the medical team. Individualised rehabilitation programme — a personalised recovery plan with exercises, milestones, and timelines tailored to the diagnosis and functional status. Scheduled consultations — regular follow-up calls with the medical coordinator and, when needed, with the treating physician (typically weekly in the first month, then monthly). Biomarker monitoring — laboratory values are coordinated with the patient's treating physician and reviewed over time against baseline. This format of follow-up allows objective evaluation of progress, timely detection of changes, and evidence-based adjustments to recommendations. Continuity of care lasts for as long as the patient needs it, with no fixed time limits.
Yes. In some cases, additional treatment cycles may be recommended. The decision regarding repeat treatment is based on the assessment of clinical response and the patient's current condition: changes on validated scales, biomarker trends, functional status, and the rate of disease progression. Repeat protocols are designed individually based on the medical board's review and may include dosage adjustments, modification of the component combination, or adaptation of the neurostimulation programme. Each case is evaluated with the same level of clinical assessment as the initial consultation.
Comorbidities are taken into account when designing the therapeutic protocol. Well-controlled conditions — such as type 2 diabetes, controlled hypertension, or stable thyroid disorders — generally do not have a significant impact on outcomes. Active inflammatory processes, untreated infections, or significant cardiac disorders may require prior stabilisation, protocol adaptation, or temporary postponement of therapy. Assessment is comprehensive: the patient's complete health profile, including all comorbidities, is taken into account. The decision is made by the medical board, considering the potential influence of each factor on the effectiveness and safety of treatment.
Cost & Programme Structure
The cost reflects the full scope of a personalised, laboratory-grade medical programme, not a single procedure. Laboratory production — each programme requires 2–3 weeks of dedicated work: processing, cultivation, and multi-level testing of the cellular material (viability, sterility, endotoxins, functional activity); all stages are performed in an in-house certified laboratory, without outsourcing, third-party cell banks, or off-the-shelf products. Multi-component approach — not one, but several individually selected therapeutic components are used: mesenchymal stem cells, T-regulatory cells, exosomes, neurostimulation, and peptide protocols; composition, dosage, and sequencing are tailored to the patient's biological characteristics. Medical board — each case is evaluated by a multidisciplinary team (neurology, immunology, molecular biology, rehabilitation); the protocol is built on the basis of molecular profiling, immune status, and the clinical trajectory of the disease. Logistics and support — the programme includes travel arrangements, transfer, accommodation, a personal coordinator, and accompaniment throughout treatment. Long-term follow-up — after therapy, the patient remains under continuous medical supervision: remote monitoring, personalised rehabilitation, biomarker assessments, and regular consultations, with no time limits. Full treatment cycle — the cost covers the entire process: from initial assessment and laboratory preparation to delivery of therapy and subsequent follow-up. Key distinction: lower-cost offers typically rely on standard protocols and do not include systematic monitoring. Our approach is an individually structured programme with full medical oversight at every stage. The difference is not in the price, but in the level of personalisation, the quality of oversight, and the depth of work with each patient.
The complete programme covers all stages of treatment — from initial assessment to long-term follow-up — and is structured as a single medical process. (1) Initial medical assessment: coordinator consultation, review of medical documentation, multidisciplinary medical board case review, and video consultation with the physicians. (2) Personalised protocol development: molecular profiling, immune status assessment, and an individualised treatment plan built on clinical data. (3) Laboratory preparation: 2–3 weeks of in-house production — processing, cultivation, testing, and verification of all therapeutic components in a certified laboratory. (4) Clinic stay: 2–5 days, including procedures, medical monitoring, and physician oversight. (5) Logistics and arrangements: private transfer, hotel-type accommodation, personal coordinator, and accompaniment. (6) Rehabilitation programme: an individualised recovery plan with milestones, prepared before discharge. (7) Medical monitoring: a wearable device for continuous remote tracking of key health indicators. (8) Long-term follow-up: regular follow-up calls, biomarker assessments, and ongoing access to the medical team with no time limit. The programme is a comprehensive medical service, not a single procedure. The cost covers all stages without breakdown into add-on options. There are no hidden charges, no separate laboratory fees, and no additional consultation costs.
All programmes are paid directly by the patient — insurance providers are not involved in billing. Upon completion of treatment, a full medical report with diagnostic and procedural codes, prepared in accordance with international standards, is provided. This allows the documentation to be used for personal medical records or for subsequent interaction with the patient's local insurance provider. The financial model is transparent: the cost is fixed in advance and does not change during the treatment course.
International patients receive full support at every stage — from initial contact to the completion of treatment and subsequent follow-up. After medical approval and confirmation of programme enrolment, the entire logistics are organised: where necessary, a visa invitation letter is issued, hotel-type accommodation in central Warsaw is booked, and a private transfer is arranged. The patient is met at arrivals and accompanied to the accommodation and to the clinic. Each patient is provided with a personal coordinator who manages the process and communication in their native language. Coordinators are available for English-, Italian-, French-, Russian-, and Polish-speaking patients; for other languages, a professional medical interpreter is engaged. The programme allows one accompanying person at no additional cost — accommodation and all transfers are included. The clinic stay typically lasts 2–5 days and covers all procedures and medical oversight.
Paediatric & Special Cases
Yes. BioCells Medical has substantial experience with paediatric patients. The clinical registry includes more than 158 children with autism spectrum disorder (ages 4–18), with 78% showing improvement in behavioural and social function on the CARS and ABC scales, and more than 90 patients with cerebral palsy with a 73% improvement in motor function on the GMFCS and GMFM scales. Paediatric protocols are adapted to the specifics of the developing nervous system: cell type, dosage, and neurostimulation parameters are selected with regard to age, body weight, and functional status. An additional level of safety is provided through enhanced monitoring at every stage of treatment. Parents or guardians are fully involved in the process — from initial assessment through follow-up — with the option to be present during procedures.
BioCells Medical delivers structured medical programmes aimed at functional stabilisation, slowing disease progression, and measurable improvement in quality of life. The objective is not a "cure" for neurological or degenerative conditions — the focus is on disease control and on the key biological mechanisms behind it. Clinical data is observational, collected within a prospective cohort analysis rather than randomised controlled trials. Results vary by diagnosis, disease stage, and the individual biological characteristics of the patient. The approach is grounded in personalised medicine and targets processes often left outside standard therapy: neuroinflammation, immune dysregulation, and metabolic dysfunction at the cellular level. Effectiveness is assessed using internationally validated clinical scales. Results are recorded in the clinical registry and used for objective evaluation of the patient's clinical trajectory.
Our clinical registry covers a broad range of neurological, autoimmune, and neuromuscular conditions. The pages on this website reflect the areas where we have the most extensive data and clinical experience. The five-component therapeutic approach targets fundamental biological mechanisms — neuroinflammation, immune dysregulation, cellular degeneration, and metabolic dysfunction — common to many chronic conditions. Even if a specific diagnosis is not on the list, individual case assessment is possible. The diagnosis is considered together with the disease stage, dynamics, biomarker profile, and the patient's functional status. A reasoned conclusion regarding the appropriateness of therapy is then provided. If the clinical basis or the expected effect is insufficient, this is stated directly in the medical conclusion.
A medical coordinator is available for a free, confidential consultation. No obligation.
Get Consultation